The individual was identified as having stage IV cT4N2M1 pulmo-adenocarcinoma and was treated with bevacizumab (7.5 mg/kg) in conjunction with carboplatin and gemcitabine. not really affected by individual age, efficiency anticoagulation or position or antiplatelet therapy. Conclusions: An individualised riskCbenefit evaluation should be performed in all sufferers with NSCLC in whom bevacizumab has been considered. … Continue reading The individual was identified as having stage IV cT4N2M1 pulmo-adenocarcinoma and was treated with bevacizumab (7